// App-Quantinova.ai

: 877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis

Researchers

Presenter

  • G. Lee

Principal Investigators

  • S. Kang

  • J. Ryou

  • J. Lim

  • D. Lee

  • H. Kwon

  • G. Ha

  • Y. Lee

Medical Centers

  • Bridgebio Therapeutics, Seongnam, Korea, Republic of,

  • LegoChem Bioscience, Daejeon, Korea, Republic of.

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Bleomycin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved